Eclipsebio’s eSENSE dsRNA™ uses next-generation sequencing to provide both quantification of contaminating dsRNA and the identification of RNA sequences and structures that lead to dsRNA generation
Eclipsebio’s partners can improve quantification of dsRNA contamination from short fragments that are missed by other assays and reduce the need for extensive purification steps by identifying points of optimization through dsRNA sequence determination
Eclipse Bioinnovations (Eclipsebio), the leader in developing precision solutions for RNA-based and RNA-targeting therapeutics, today announced the launch of its eSENSE dsRNA™ assay. eSENSE dsRNA is a next-generation sequencing method for the robust quantification, localization, and optimization of double-stranded RNA (dsRNA) contaminants in RNA-based vaccines and therapeutics.
“By limiting translation and RNA stability, dsRNA contamination is a major challenge for the development of an effective RNA-based therapeutic,” said Eclipsebio Co-Founder and CEO Peter Chu, Ph.D. “eSENSE dsRNA provides actionable insights into how dsRNA is generated during in vitro transcription providing the data needed to guide sequence- and structure-based optimizations to reduce contamination and the need for extensive drug substance purification.”
eSENSE dsRNA overcomes the limitations of current antibody-based methods for detecting dsRNA contamination by using a next-generation sequencing approach that can detect short dsRNA fragments. In addition to providing reproducible quantification of dsRNA levels similar to dot blot and ELISA methods, the assay also identifies where dsRNA generation begins and ends, providing Eclipsebio’s biopharma partners with sequence optimizations to reduce dsRNA generation during RNA synthesis. eSENSE dsRNA will be offered exclusively as part of Eclipsebio’s eMERGE platform for RNA-based medicine characterization and optimization.
Eclipsebio will unveil eSENSE dsRNA at the RNA Leaders USA Congress on September 4, 2024.
Source – BusinessWire